Skip to main content
. 2017 Nov 6;9(1):766–773. doi: 10.18632/oncotarget.22332

Table 3. Response rates.

Response n (%)
CR 7 (28)
CRU* 9 (36)
PR 4 (16)
Stable --
PD 4 (16)
Unevaluable 1 (4)
Total 25

CR, complete response; CRu, Complete response, unconfirmed; PR, partial response; PD, progressive disease.